|
Aug 7
|
Rani Therapeutics Reports Second Quarter 2025 Financial Results; Provides Corporate Update
|
|
Jul 15
|
Rani Therapeutics Holdings, Inc. Announces Pricing of $3.0 Million Registered Direct Offering
|
|
Jul 14
|
Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous Delivery
|
|
Feb 15
|
Rani Therapeutics Holdings, Inc.'s (NASDAQ:RANI) largest shareholders are individual investors who were rewarded as market cap surged US$11m last week
|
|
Nov 14
|
Rani Therapeutics Reports Third Quarter 2024 Financial Results; Provides Corporate Update
|
|
Oct 9
|
Pleasing Signs As A Number Of Insiders Buy Rani Therapeutics Holdings Stock
|
|
Oct 8
|
Rani Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit
|
|
Jul 29
|
Rani Therapeutics to Participate in August Investor Conferences
|
|
Jun 24
|
Rani Therapeutics Announces Partnership with ProGen on Development of Oral Obesity Treatment
|
|
May 14
|
Rani Therapeutics to Participate in May Investor Conferences
|
|
May 9
|
Rani Therapeutics to Present Clinical and Preclinical Data on Oral Delivery of an Ustekinumab Biosimilar via the RaniPill® Capsule at Digestive Disease Week 2024
|
|
May 9
|
RANI: 1Q:24 Results
|
|
May 8
|
Rani Therapeutics Q1 2024 Earnings: Financial Performance and Strategic Updates
|
|
May 6
|
Rani Therapeutics Reports First Quarter 2024 Financial Results; Provides Corporate Update
|
|
May 2
|
Favourable Signals For Rani Therapeutics Holdings: Numerous Insiders Acquired Stock
|
|
Mar 21
|
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Q4 2023 Earnings Call Transcript
|
|
Mar 21
|
RANI: 2023 Results
|
|
Mar 21
|
Q4 2023 Rani Therapeutics Holdings Inc Earnings Call
|
|
Mar 20
|
Rani Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Corporate Update
|
|
Mar 15
|
Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results
|